Post

Agenda for December 2026 joint Anti-Infectives & Respiratory Advisory Committee meeting

Agenda for December 2026 joint Anti-Infectives & Respiratory Advisory Committee meeting

Source: PHARMAC

Information on what the Anti-Infectives & Respiratory Advisory Committees will consider at their meeting in December 2026.

A joint meeting has been scheduled to consider a number of bronchiectasis-related matters that would benefit with input from both committees.

Matters Arising

Review of the duration of azithromycin treatment for non-cystic fibrosis bronchiectasis in children

The Committee will discuss potential changes to the funded duration of treatment with azithromycin in children with non-cystic fibrosis bronchiectasis.

Review of azithromycin for the treatment non-cystic fibrosis bronchiectasis in adults

The Committee will discuss the use of azithromycin for the treatment of adults with non-cystic fibrosis bronchiectasis.

Review of other antibiotics for non-cystic fibrosis bronchiectasis in children and adults

The Committee will discuss the role of various antibiotics for children and adults with non-cystic fibrosis bronchiectasis, including potential changes to current funding and access criteria.

Consideration of additional strengths of hypertonic saline for nebulisation

The Committee will discuss the availability of additional strengths of hypertonic saline for nebulisation for conditions such as cystic fibrosis.

Advisory meeting agenda setting

The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.

Original source: https://nz.mil-osi.com/2026/11/20/agenda-for-december-2026-joint-anti-infectives-respiratory-advisory-committee-meeting/